Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.

Cancer immunology, immunotherapy : CII - 1 May 2020

Kerepesi Csaba, Bakacs Tibor, Moss Ralph W, Slavin Shimon, Anderson Colin C

Abstract excerpt

More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to healthy self-tissues in the majority. We have proposed that a major mechanism of irAEs is similar to a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Mutation

Share to Neoplasms

Share to Self Tolerance

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 32152702
DOI: 10.1007/s00262-020-02543-6
PMCID: PMC7183506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.PMID 32152702Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read ↗

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid TumorsSemantic proximity Read ↗

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read ↗

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity Read ↗

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.